Skip to main content

Table 3 Primary and secondary endpoints

From: Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study

 

UFH (n = 20)

UFH + tirofiban (n = 20)

P value

Platelet/Monocyte counts at the end of CRRT

   

   Platelet count, × 109/L, mean ± SD

87 ± 41.1

158 ± 45.3

0.001

   Monocyte count, × 106/L, mean ± SD

945 ± 77.3

1,394 ± 151

0.012

   Platelet-monocyte aggregates as a percentage, mean ± SD

27.5 ± 9.3

3.9 ± 2.1

0.001

Bleeding events during CRRT

   

   Minor bleeding, number

2

1

0.560

   Major bleeding, number

0

0

1

Platelet transfusions during CRRT

   

   Platelet units per patient per day, mean ± SD

0.05 ± 0.02

0

0.016

Outcome

   

   Intensive care unit mortality rate, number (percentage)

8 (40)

7 (35)

0.752

   Hospital mortality rate, number (percentage)

8 (40)

7 (35)

0.752

   SAPS II predicted mortality rate as a percentage

36.9

41.4

-

   Observed-to-expected mortality ratio

1.08

0.85

-

   95% confidence interval for the observed-to-expected mortality ratio

0.46, 1.97

0.34, 1.59

-

  1. Values are presented as number of patients or mean ± standard deviation (SD). CRRT, continuous renal replacement therapy; SAPS, Simplified Acute Physiology Score; UFH, unfractioned heparin.